About Mark Edwards
Mark Edwards has over two decades of experience in negotiating and analyzing biopharma alliances. As founder and managing director of Recombinant Capital (Recap) from 1988 until its sale to Deloitte in 2008, Mr. Edwards supervised the creation and maintenance of several databases relating to the development and commercialization of pharmaceutical products, including the Recap Corporate Alliances Database. Over this period, Mr. Edwards and Recap was retained by more than 50 companies to assist in the negotiation of biopharma alliances. His consulting clients have included Abbott, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Millennium, Merck, Pfizer, PTC Therapeutics, Roche and Tularik. In 2008, Mr. Edwards was awarded a Lifetime Achievement Award by the American Liver Foundation for "two decades of leadership, thoughtful insights and detailed analysis of the biotechnology industry."
From 2008 through 2010, Mr. Edwards was the managing director of Deloitte Recap LLC, a wholly-owned subsidiary of Deloitte LLP. In this capacity, he ran Deloitte Recap and consulted on behalf of Deloitte on a variety of client engagements.
In January 2011, Mr. Edwards founded Bioscience Advisors, Inc. (Biosci), a consulting and database firm focused on biopharma alliances. Biosci has created a database, BiosciDB, that contains copies of over 12,000 license, development, co-development, joint venture, distribution, asset purchase and other arm's-length agreements that have been publicly filed with the U.S. Securities and Exchange Commission (SEC). Biosci analysts have obtained unredacted copies of approximately 8,500 of these agreements, with the majority obtained via Freedom of Information Act (FOIA) requests.
Biosci also launched a public discussion forum, BiosciBD, where biopharma licensing professional and other interested parties can share and enhance best practice in negotiating, structuring and managing alliances.
Mr. Edwards is a charter Certified Licensing Professional as established by the Licensing Executive Society. He is on the board of directors of AcelRx and Calibr and has previously served on the boards of Allos Therapeutics, CombiMatrix and Ontogen. He holds a Bachelor of Arts degree in Political Science and Economics and an MBA, both from Stanford University.